Annie Young

Annie Young

Auto-generated profile, based on publicly available information

Annie Young

Warwick Medical School, University of Warwick, Coventry, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2020 in Blood
Verified
Journal Article
Closed access
FMFrits I. Mulder
Frits I. Mulder
FBFloris Bosch
Floris Bosch
AYAnnie M. Young
Annie M. Young
AMAndrea Marshall
Andrea Marshall
RMRobert D. McBane
Robert D. McBane
NENick van Es
Nick van Es
Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent results. This systematic review and meta-analysis compared the efficacy and safety of DOACs and low-molecular-weight heparins (LMWHs) in these patients. MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and conference proceedings were searched to identify relevant randomized controlled trials. Additional data were obtained from the original authors to homogenize definitions for all study outcomes. The primary efficacy and safety outcomes were recurrent VTE and major bleeding, respectively. Other outcomes included the composite of recurrent VTE and major bleeding, clinically relevant nonmajor bleeding (CRNMB), and all-cause mortality. Summary relative risks (RRs) were calculated in a random effects meta-analysis. In the primary analysis comprising 2607 patients, the risk of recurrent VTE was nonsignificantly lower with DOACs than with LMWHs (RR, 0.68; 95% CI, 0.39-1.17). Conversely, the risks of major bleeding (RR, 1.36; 95% CI, 0.55-3.35) and CRNMB (RR, 1.63; 95% CI, 0.73-3.64) were nonsignificantly higher. The risk of the composite of recurrent VTE or major bleeding was nonsignificantly lower with DOACs than with LMWHs (RR, 0.86; 95% CI, 0.60-1.23). Mortality was comparable in both groups (RR, 0.96; 95% CI, 0.68-1.36). Findings were consistent during the on-treatment period and in those with incidental VTE. In conclusion, DOACs are an effective treatment option for patients with cancer and acute VTE, although caution is needed in patients at high risk of bleeding.

1 December 2020 in The Lancet Oncology
Verified
Journal Article
Closed access
AYAnnie M Young
Annie M Young
ACAndreas Charalambous
Andreas Charalambous
RORay I Owen
Ray I Owen
BNBernard Njodzeka
Bernard Njodzeka
WOWendy H Oldenmenger
Wendy H Oldenmenger
WSWinnie K W So
Winnie K W So

29 January 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
AMAndrea Marshall
Andrea Marshall
MLMark Levine
Mark Levine
CHCatherine Hill
Catherine Hill
DHDanielle Hale
Danielle Hale
JTJenny Thirlwall
Jenny Thirlwall
AYAnnie M. Young
Annie M. Young

2 July 2020 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
AYAnnie M Young
Annie M Young
FAFredrick D. Ashbury
Fredrick D. Ashbury
LSLidia Schapira
Lidia Schapira
FSFlorian Scotté
Florian Scotté
CRCarla I Ripamonti
Carla I Ripamonti
IOIan Olver
Ian Olver

25 April 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
RARaza Alikhan
Raza Alikhan
KGKeith Gomez
Keith Gomez
AMAnthony Maraveyas
Anthony Maraveyas
SNSimon Noble
Simon Noble
AYAnnie Young
Annie Young
THThe British Society For Haematology
The British Society For Haematology

26 April 2014 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
AWAndrew Weaver
Andrew Weaver
SLSharon B. Love
Sharon B. Love
MLMark Larsen
Mark Larsen
MSMilensu Shanyinde
Milensu Shanyinde
RWRachel Waters
Rachel Waters
LTLionel Tarassenko
Lionel Tarassenko